

Lungair

10 mg Tablet

Montelukast BP 10 mg.

Composition :

Lungair Tablet: Each film-coated tablet contains Montelukast Sodium BP equivalent to Montelukast 10 mg

Indications :

Montelukast (Lungair) is indicated in the treatment of asthma as add on therapy in those patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom 'as needed' short acting agonists provide inadequate clinical control of asthma.

Pharmacology :

The cysteinyl leukotrienes (LTC₄,LT₀₄,LTE₄) are products of arachidonic acid metabolism and are released from various cells, and including mast cells and eosinophils. These eicosanoids bind to cysteinyl leukotriene receptors (CysLT) found in the human airway.

Montelukast is an orally active compound that binds with high affinity and selectivity to the CysLT₁ receptor. Montelukast inhibits physiologic action of LTD₄ at the CysLT₁ receptor without any agonist activity.

Why Used It :

Asthmatic patients in whom Lungair is indicated in asthma, it can also provide symptomatic relief of seasonal allergic rhinitis. Lungair is also indicated in the prophylaxis of asthma in which the predominant component is exercise induced bronchoconstriction.

Dosage & Administration :

The dosage for adult is 15 years of age and older with asthma or with asthma and concomitant seasonal allergic rhinitis, is one 10 mg tablet daily to be taken in the evening.

Contra-Indications :

Hypersensitivity to any component of this product.

Adverse Drug Reaction :

Montelukast appears to be well tolerated. In clinical trials, the most common adverse effect reported was headache occurring in approximately 18 % of patients. Rash, dyspepsia, dizziness, and abdominal pain were all reported in less than 2% of patients. Elevated liver transaminases have been reported with Montelukast use, but not at a greater incidence than with placebo.

Nervous System/Psychiatric: Depression, headache, insomnia, agitation.

A small percentage of pediatric patients have experienced diarrhea, sinusitis and otitis media during Montelukast clinical trials.

Precautions :

Montelukast is not indicated for use in the reversal of bronchospasm in acute asthma attacks. Including status asthmatic is patients should be advised to have appropriate rescue medication available.

Drug Interaction :

Montelukast may be administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma. In drug-interactions studies, the recommended clinical dose of Montelukast did not have clinically important effects on the following medicinal products theophylline, prednisone, prednisolone, oral contraceptives, terfenadine, digoxin and warfarin. Caution should be exercised, particularly in children, when Montelukast is coadministered with phenytoin, phenobarbital and rifampicin.

Use In Pregnancy & Lactation :

Montelukast is classified as pregnancy Category B. The drug has been shown to cross the placenta & of pregnant rats and rabbits. but there have been no reports of its use in pregnant women. Montelukast is also known to be excreted into breast-milk, but only limited information is available on the significance of this finding. Caution should be used prior to initiating Montelukast therapy in nursing mothers.

Overdose Effects :

Symptoms: Abdominal pain, somnolence, thirst, headache, vomiting, and psychomotor hyperactivity.

Management: Supportive and symptomatic treatment. If indicated, unabsorbed material should be removed from the GI tract.

Storage Conditions :

Store below 30°C temperature at a cool and dry place, away from light and moisture. Keep all medicine out of the reach of children.

How Supplied :

Lungair tablet: Each Box containing 3X10's tablet in Alu-Alu blister packs.

Manufactured by:
GUARDIAN
Healthcare Ltd.
Amtola, Zirabo, Ashulia
Dhaka, Bangladesh.